Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review

Overview of attention for article published in Frontiers in oncology, August 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 23,141 followers.

RT @DrImranSheikh: Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRA…

22 Aug 2022

Reply Repost Favourite

Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review: BRAF gene has been identified as an oncogenic driver and a #oncology… https://t.co/uoBtr

20 Aug 2022

Reply Repost Favourite

New research: Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review: BRAF gene has been identified as an oncogenic driver and a… https://t.co/32

19 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.